The Etiology of Ring Lesions on Diffusion-Weighted Imaging
NeuroRadiol J 27:280-287, Finelli, P. & Foxman, E.B., 2014
Internuclear Ophthalmoplegia
Arch Neurol 62:714-717, Keane,J.R., 2005
Lesions of the Corpus Callosum: MR Imaging and Differential Considerations in Adults and Children
AJR 179:251-257, Bourekas,E.C.,et al, 2002
Diffusion-Weighted MR Imaging of the Brain
Radiology 217:331-345, Schaefer,P.W.,et al, 2000
Clinical Presentations of Vascular Malformations of the Brain Stem:Comparison of Angiographically Positive and Negative Types
JNNP 52:167-175, Abe,M.,et al, 1989
Non Ischaemic Causes of Lacunar Syndromes:Prevalence and Clinical Findings
JNNP 52:1188-1190, Anzalone,N.&Landi,G., 1989
Magnetic Resonance Imaging of the Central Nervous System Council on Scientific Affairs
Report of the Panel on MRI, JAMA 259:1211-12221988., , 1988
MR Imaging of the Corpus Callosum:Normal and Pathologic Findings and Correlation with CT
AJNR 9:649-656, Reinarz,S.J.,et al, 1988
The Clinical & Pathological Spectrum of Brainstem Vascular Malformations
Arch Neurol 37:25-29, Stahl,S.M.,et al, 1980
Clinical Correlations of Periodic Lateralized Epileptiform Discharges
Clin Electroenceph 8:191-202, Porecha,H.P.&Reilly,E.L., 1977
Bilateral Sixth Nerve Palsy
Arch Neurol 33:681, Keane,J.R., 1976
The Geography of Neurology
BMJ 2:506, Spillane,J.D., 1972
Brain Stem Arteriovenous Malformations
Arch Ophthalmol 86:255, Lessel,S.,et al, 1971
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020
Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Cryptococcal Meningoencephalitis in a Patient with Multiple Sclerosis Treated with Fingolimod
JAMA Neurol 72:1203-1205, Zhan, Y.,et al, 2015
Daclizumab-Induced Adverse Events in Multiple Organ Systems in Multiple Sclerosis
Neurol 82:984-988, Oh, J.,et al, 2014
Monosymptomatic Clinically Isolated Syndrome with Sudden Sensorineural Hearing Loss
The Neurologist 18:302-305, Anagnostouli, M.C.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Reemergence of PML in Natalizumab-Treated Patients--New Cases, Same Concerns
NEJM 361:1041-1043, Major,E., 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008
Glatiramer Acetate--Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma
Arch Neurol 65:1378-1379, Madray,M.M.,et al, 2008
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
Differential Diagnosis of Bilateral Thalamic Lesions
Clin Neuroradiol 17:3-22, Linn,J.,et al, 2007
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
NEJM 353:375-381, Langer-Gould,A.,et al, 2005
Oligodendroglioma and Multiple Sclerosis. A Case Report.
Neurocirugia (Astur) 15:378-83, de la lama,A.,et al, 2004
Multiple Sclerosis and Gliomas. Clinical Remarks on 10 Cases and Critical Review of the Literature.
J Neurosurg Sci 48:129-33, Isadori,A.,et al, 2004
MR Features of Diseases Involving Bilateral Middle Cerebellar Peduncles
AJNR 24:1946-1954, Okamoto,K.,et al, 2003
Concurrence of Multiple Sclerosis and Intracranial Glioma. Report of a Case and Review of the Literature.
Clin Neuropathol 22:304-308, Shuangshoti,S.,et al, 2003
Sandlike Appearance of Virchow-Robin Spaces in Early Multiple Sclerosis:A Novel Neuroradiologic Marker
AJNR 23:376-380, Achiron,A.&Faibel,M., 2002
Bacterial Infection as a Cause of Multiple Sclerosis
Lancet 360:352-353, Wolfson,C. &Talbot,P., 2002